StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for DERM yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $6.36 | $6.25 | -1.73% | 0.4M |
| 05-19 | $6.14 | $6.15 | +0.16% | 0.3M |
| 05-20 | $6.15 | $6.17 | +0.33% | 0.3M |
| 05-21 | $6.06 | $6.21 | +2.48% | 0.2M |
| 05-22 | $6.26 | $5.96 | -4.79% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $15.92M | $61.24M | $45.17M | $28.15M |
Operating Income | $-1.49M | $-8.17M | $-7.73M | $-6.20M |
Net Income | $-2.23M | $-11.43M | $-10.18M | $-7.87M |
EPS (Diluted) | $-0.08 | $-0.47 | $-0.43 | $-0.34 |
Total Assets | $91.53M | $94.59M | $85.19M | $81.16M |
Total Liabilities | $60.70M | $62.74M | $59.29M | $61.91M |
Cash & Equivalents | $27.22M | $24.09M | $24.95M | $20.29M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 27.31M | 24.50M | 23.63M | 22.95M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.